drugset / Trial / NCT04377243

Immunotherapy of Chronic Kidney Failure

NCT04377243 ↗

Phase 2 Unknown 20 enrolled Immunitor LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

Kidney failure can result from inflammatory renal disease in the context of autoimmunity because the kidney is targeted by host's immune response against self. There are many causes to this, but abnormal kidney function tests, i.e., BUN and creatinine, can reveal the disease. Oral delivery of kidney cells is ought to produce the immune tolerance - phenomenon is known as oral tolerance. Preliminary studies produced convincing evidence that this hypothesis holds true and has not produced any adverse side effects. Intended open label Phase II aims to confirm these findings.

Timeline

Start
2020-06-16
Primary completion
2021-05-15
Completion
2021-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject V8 Unknown 850 mg Oral